Drugs /

yttrium y 90-labeled anti-fzd10 monoclonal antibody otsa101

Back to Drugs List

Overview

NCI Definition [1]:
A radioimmunoconjugate composed of a humanized monoclonal antibody (MoAb) OTSA101 against FZD10 and labeled with yttrium y 90, with potential antineoplastic activity. The MoAb moiety of yttrium Y 90-labeled anti-FZD10 monoclonal antibody OTSA101 binds to FZD10, thereby delivering a cytotoxic dose of beta radiation to FZD10 positive tumor cells. FZD10 (also called CD350), a member of the Frizzled family of G protein-coupled receptors that is involved in the Wnt/beta-catenin/TCF signaling pathway, is overexpressed in a variety of cancer cell types but undetectable in normal, healthy human tissues except for the placenta.

Clinical Trials

View Clinical Trials for yttrium y 90-labeled anti-fzd10 monoclonal antibody otsa101

Yttrium y 90-labeled anti-fzd10 monoclonal antibody otsa101 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating yttrium y 90-labeled anti-fzd10 monoclonal antibody otsa101, 1 is phase 1 (1 open).

Synovial sarcoma is the most common disease being investigated in yttrium y 90-labeled anti-fzd10 monoclonal antibody otsa101 clinical trials [2].

Drug Details

Synonyms [2]:
otsa101-dtpa-90y
Drug Target(s) [2]:
FZD10
NCIT ID [1]:
C99168

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.